VANCOUVER, Aug. 13, 2019 /PRNewswire/ – Harvest A single Inc. (“Harvest One” or the “Company”) (TSXV: HVTOTCQX:HRVOF), by means of its wholly-owned subsidiary Satipharm Ltd. (“Satipharm”), nowadays announced constructive outcomes of a Phase two clinical trial of its CBD GelPell® capsules in the management of Therapy Resistant Epilepsy (TRE) have been published in Epilepsy & Behaviour, a bimonthly peer-reviewed healthcare journal covering behavioral elements of epilepsy.
Highlights include things like
- Phase two open label clinical trial is aimed at measuring security and efficacy of Satipharm CBD capsules for lowering seizure frequency in young children with refractory, or therapy-resistant, epilepsy
- The median reduction of month-to-month seizures was -82% in the 12-week therapy period in therapy-resistant young children when added to present drugs
- 56% who began the therapy had a reduction of at least 50% in total quantity of seizures in the course of the whole therapy period, compared to observation
- 73% have been rated as “very a great deal enhanced/improved” in all round situation on the Caregiver International Impression of Improvement scale
- 82% have been rated as “very a great deal decreased/reduced”
- A imply 73.four% reduction from baseline month-to-month seizure frequencies was observed
- Two individuals have been completely seizure-no cost inside five weeks of therapy
- An further seven individuals reported >50% seizure frequency reduction
A fulsome description of the study and outcomes can be located in the Harvest A single background document obtainable on our internet site at https://www.harvestone.com/portfolio/satipharm/#clinical-trials
The outcomes of our second stage of clinical trials on our Satipharm 50mg CBD GelPell® solutions are incredibly encouraging for the individuals we serve, our shareholders and our corporation. We continue to be focused on the ideal in class overall health, wellness, and self-care solutions at Harvest A single and we think that our special solutions, which includes the proprietary GelPell®, will be very sought just after as cannabis legalization requires hold about the globe.
Grant Froese, Chief Executive Officer of Harvest A single
GelPell® capsules include complete spectrum hemp extract CBD in a seamless gelatine bead. This bead is placed inside a challenging gastro-resistant capsule making certain the release of CBD in the modest intestine exactly where it has the greatest impact. Manufactured in Switzerland and EU GMP Certified, every single 50mg GelPell® capsule has been clinically verified to strengthen the body’s absorption of CBD and other cannabinoids. They are effortless to take and include a constant and precise dose of CBD.
“The efficacy of Satipharm’s CBD capsules as an add-on therapy in the therapy of pediatric, intractable epilepsy has been shown. In addition, these outcomes examine favourably to other comparable research of cannabidiol” stated Prof. Uri Kramer, Director of Pediatric Epilepsy Service, Tel Aviv Sourasky Healthcare Centre and Principal Investigator of the trial. “Importantly, the substantial reductions in seizure frequency though demonstrating satisfactory security and tolerability profile, in these incredibly tricky to treat individuals, have the possible to be a life-altering occasion for these individuals and their households. I would be tremendously interested in prescribing such standardized and clinically tested item as Satipharm’s 50mg CBD GelPell®”
Uncover complete facts of the Clinical Trial outcomes right here:
About Therapy Resistant Epilepsy (TRE)
Epilepsy encompasses a wide variety of chronic syndromes characterized by recurrent, unprovoked, and unpredictable seizures. The illness is estimated to impact more than 65 million persons worldwide, which includes roughly .six% of young children beneath the age of 18 , 82% of whom will be beneath the age of 10 . Therapy-resistant epilepsy (TRE), defined as failure to accomplish sustained seizure remission just after suitable calibration of at least two antiepileptic drugs (AEDs), impacts roughly 30% of individuals with epilepsy . Apart from the serious morbidity and considerably improved mortality amongst individuals with TRE , , early onset comes along with higher incidence of cognitive, behavioral, motor, and neurodevelopmental delays .
Accessing Satipharm 50mg CBD GelPell® Capsules
Satipharm CBD 50mg GelPell® capsules are obtainable in the UK by means of Well being Property who distribute to pharmacies and healthcare pros.
+44 () 1420 487501
Satipharm CBD 50mg GelPell® capsules are obtainable in Australia through the Therapeutic Goods Administration (TGA) Unique Access Scheme (Category B) or by means of the Authorised Prescriber Scheme. Individuals wishing to access medicinal cannabis solutions ought to talk about access with their doctor and make themselves familiar with the processes by reading the TGA guidance at www.tga.gov.au. ‍Once the doctor has the expected approval, this prescription can then be sent to our distributor, Well being Property International, who will arrange delivery to a dispensing pharmacy.
About Harvest A single Cannabis Inc.
Harvest A single is a international customer packaged goods corporation that develops and distributes premium overall health, wellness, and way of life solutions to individuals and buyers in regulated markets about the globe. The Company’s portfolio of premium solutions is made to boost top quality of life. Shareholders have substantial exposure to the whole cannabis worth chain by means of 4 wholly-owned subsidiaries: United Greeneries, a Licensed Producer Satipharm (healthcare and nutraceutical) Dream Water International and Delivra (customer solutions with an emphasis on sleep, discomfort, and anxiousness), and a minority interest in Burb Cannabis (retail operations). For extra information and facts, please visit www.harvestone.com.
Satipharm is a health and wellness corporation which is specialised in the improvement and manufacture of cannabinoid-primarily based solutions from the hemp plant. Our mission is to provide the highest top quality solutions that are made particularly with the desires of our clients in thoughts. For extra information and facts, please visit www.satipharm.com.
Original press release